Innovation Catalyst Program

A purpose-built catalyst for innovative Australian MedTech translation. Tell us the clinical problem you want to solve and how you plan to solve it. We'll give you an early, honest assessment of the translation risks that matter most, and what it would take to address them.

Personalise
Innovation Catalyst Program

Program overview

Many promising MedTech innovations stall when faced with the complexities of clinical adoption, despite successfully overcoming technical challenges. What seems straightforward quickly becomes complicated: solutions require unexpected changes to clinical workflows; key stakeholders are overlooked, or the business case fails to account for who bears the costs and who stands to benefit. The Innovation Catalyst Program helps you identify those risks early in the development journey, while they are financially and logistically easier to address.

We draw from our extensive clinical, technical, regulatory and commercial networks to give every innovator a structured first assessment, identifying specific areas where the evidence indicates our experts' time will have the most impact.

We specialise in medical devices and software-based solutions and currently do not support projects focused on drug development, biologics or process improvements.

Program structure

The program runs in three stages, from defining the need, to deciding whether and how to move forward. Each stage ends with a clear deliverable and a decision point, so you only invest in the next step when the evidence supports it.

IHealthE Infographic ICP 2026 Updated IHealthE Infographic - ICP 2026

Who should apply?

Individuals or teams developing an innovative solution to an unmet healthcare need. Applicants should have some familiarity with the intended clinical setting and its stakeholders. You can apply as an individual innovator, although we strongly encourage having a clinician as part of your core team.

Solutions may be at an early stage of development: you don't need a fully developed product to apply, provided there is a clearly defined clinical need.

Why apply?

Every EOI submission goes through a Define work package and receives:

  • A structured review of the key translation risks in your proposed problem and solution space.
  • A tailored set of questions from our MedTech translation experts, centred on your largest risks. 
  • An initial assessment of key risks that reflects the progress you have already made to date. 
  • A clear recommendation on what to do next: 
    • Progress to a Validate work package 
    • Resubmit in a future intake of the Innovation Catalyst Program 
    • Reconsider the unmet need and proposed solution. 

Projects accepted for further IHealthE support progress to the Validate stage, where teams also receive an agreed scope of work (valued up to $5,000). This stage focuses on validating and developing strategies to address the most critical risks to your project's success. Teams also gain access to IHealthE's expert advisory networks, MedTech Mentors and opportunities to work alongside us on the Prince of Wales Hospital campus. IHealthE takes no equity or ownership of your intellectual property unless otherwise agreed.

What to expect

Your response shapes the outcome and timeline of your program experience. We prioritise engagement with innovators who respond promptly and demonstrate progress by providing relevant, quality evidence and/or clear plans to address identified risks. If we don't receive a response within 3 weeks of your initial assessment, we'll close your application, and a new EOI will be required to re-engage with the program.

While every applicant receives a written assessment, follow-up discussions and further support are offered selectively.

Intakes. We run three intakes a year, with up to 25 EOIs per intake. Closing dates in 2026: 2 April, 31 July and 30 November. If an intake fills early, your EOI rolls into the next one.

Confidentiality and IP. Please keep your EOI non-confidential: describe the problem and your approach without disclosing the proprietary know-how you need to protect. If you progress to Validate, we work under a confidentiality agreement. IHealthE takes no equity and does not assert IP rights in your innovation; any co-creation of IP with collaborators during the program is assessed and agreed with you.

Kraken Coding founder John Shanks joined IHealthE’s Innovation Catalyst Program in 2024 to support the development of Clinical Branches, a clinical decision support platform helping healthcare professionals access evidence-based guidance at the point of care. Since then, Kraken Coding has secured a $1.93 million NSW Medical Devices Fund grant to further develop the platform. 

The support went straight at those gaps: stakeholder identification, a regulatory strategy for the ML component, an IP protection strategy, and help with a major grant application. Two years on, the IHealthE advisors still provide feedback.

John Shanks
Kraken Coding (Founder)

FAQ

    • Define: There is no charge for EOI submission and a Define package of work.
    • Validate: There is no charge for a Validate scope of work in 2026.
    • Prioritise & De-risk: Fee-based and scoped with you to address the most critical risks, drawing on our expertise, facilities and network.
  • Every applicant receives a written assessment. We invite innovators to a follow-up conversation where their responses show a strong fit with IHealthE aims and expertise and a clear path to reducing the highest risks.

  • You keep your finalised assessments. Where the idea could be reshaped to better align with our capabilities and expertise, we'll invite you to resubmit in a future intake; where another organisation is a better fit, we'll suggest a referral.

  • No. We take no equity and do not assert IP rights. Any IP co-created with collaborators is assessed and agreed with you.

Strategy & Innovation Team

There are a number of ways to start your innovation process with Tyree IHealthE. Fill in a request for a consultation using this short form and one of our team will be in touch.

Dr Ian Goon | COO & Head of Strategy and Innovation
Scott Hebenton | Strategy and Innovation Project Officer
Dr Claire Bridges | Clinical Engagement Project Officer 
Prof Peter Spencer | Professor of Practice
Prof John Parker | Professor of Practice

View the full team